Antibodies targeting CNTN1 were first described in 2012 by Devaux et al. in sera of a small subset of patients presenting with GBS-like and CIDP-like symptoms using combined cell-binding and nerve-binding assays [5]. Here, CNTN1 is linked to chronic inflammatory demyelinating polyradiculoneuropathy.